Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188952
Title: | Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma |
Author: | Puig, Noemí Contreras, María Teresa Agulló, Cristina Martínez López, Joaquín Oriol Bosch, Albert Blanchard, María Jesús Ríos, Rafael Martín, Jesús Iñigo, María Belén Sureda, Anna Hernández, Miguel Teodoro De La Rubia, Javier González Calle, Verónica Krsnik, Isabel Cabañas, Valentín Palomera, Luis Moraleda, José María Bargay, Joan Cedena, María Teresa Paiva, Bruno Rosiñol, Laura Bladé, J. (Joan) San Miguel, Jesús Lahuerta, Juan José Mateos, María Victoria |
Keywords: | Anticossos monoclonals Espectrometria de masses Monoclonal antibodies |
Issue Date: | 31-May-2022 |
Publisher: | American Society of Hematology |
Abstract: | Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2021006762 |
It is part of: | Blood Advances, 2022, vol. 6, núm. 11, p. 3234-3239 |
URI: | http://hdl.handle.net/2445/188952 |
Related resource: | https://doi.org/10.1182/bloodadvances.2021006762 |
ISSN: | 2473-9537 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
advancesadv2021006762.pdf | 919.58 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License